Fig. 1.
![Fig. 1. Cell death induction by the combination of rituximab and normal human AB serum. / Cells from a representative CD20++ patient with follicular lymphoma (FL) were incubated in the presence or absence of 50 μg/mL rituximab and 10% AB (R+AB) for 24 hours and analyzed by flow cytometry. (A) Flow cytometric plots showing FSC/SSC pattern. (B) Flow cytometric plots showing annexin V binding. (C) Histogram showing mitochondrial transmembrane potential after staining with DiOC6[3].](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/98/9/10.1182_blood.v98.9.2771/4/h82111711001.jpeg?Expires=1735543572&Signature=T67p-~wNnyXB0wuoIoF6eKQ58WkR3xkqmsdIxywhBqq01j4YH~DAOVyk24XN96p~qjdR6Xh9yKh0DO1IxqD69CpYOPDVOLu6bXxkPIt1QX2sYELdnCgWLicoMr6KUEK9z1597VRAnC-WfzBdY7x6SqUQP4ia8nyJiO5nmYKAgPGpkSRZN0r9t1CGf5Q024P2xxHy0BriaUvxQfIqVynaoTFR2KuhJBGOfIo-ElJaZcgdKPYasWzQbXHbXTBgOxGgmbG8l18kcqOqmJfq1oKoIolJmHLi1euSS5l-rI0poJ1oYRFt3kQjEVTYDfwZ2IjdTlTvylpSigVVBX-SCLb9pQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Cell death induction by the combination of rituximab and normal human AB serum.
Cells from a representative CD20++ patient with follicular lymphoma (FL) were incubated in the presence or absence of 50 μg/mL rituximab and 10% AB (R+AB) for 24 hours and analyzed by flow cytometry. (A) Flow cytometric plots showing FSC/SSC pattern. (B) Flow cytometric plots showing annexin V binding. (C) Histogram showing mitochondrial transmembrane potential after staining with DiOC6[3].
